This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Mdm2 p53 binding protein homolog (MDM2)	<p>A study in cell culture suggests that targeting MDM2 on the cell membrane could help treat cancer. In multiple cancer cell lines, a peptide containing an MDM2-binding domain induced cell death whereas a control peptide did not. Next steps include evaluating the effects of the MDM2-binding peptide in animal models of cancer. Johnson & Johnson's JNJ-26854165, an MDM2 inhibitor, is in Phase I testing for solid tumors.</p> <p>SciBX 3(2); doi:10.1038/scibx.2010.42 Published online Jan. 14, 2010</p>	<p>Patented for use in cancer; licensed to Innomab Inc.; available for licensing from The Research Foundation of The State University of New York</p> <p>Contact: Guven Yalcintas, The Research Foundation of The State University of New York, Albany, N.Y. phone: 518-434-7077 e-mail: guven.yalcintas@rfsuny.org</p>	<p>Sarafraz-Yazdi, E. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 14, 2009; doi:10.1073/pnas.0909364107</p> <p>Contact: Matthew R. Pincus, New York Harbor VA Medical Center, Brooklyn, N.Y. e-mail: matthew.pincus2@med.va.gov</p> <p>Contact: Josef Michl, SUNY Downstate Medical Center, Brooklyn, N.Y. e-mail: jmichl@downstate.edu</p>